Loading
A phase 2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, run by Maxinovel Pty., Ltd., now recruiting.
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia is a phase 2 interventional study registered as NCT07743112 by Maxinovel Pty., Ltd., with 43 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-09-01. Interventions recorded: MAX-40279, Azacitidine and Venetoclax.
Shares Acute myeloid leukaemia in older or unfit patients, BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.